非酒精性脂肪性肝病与心血管疾病的临床相关性研究进展

Nonalcoholic fatty liver disease and cardiovascular disease clinical correlation research progress

目的探讨非酒精性脂肪性肝病与心血管疾病的临床相关性研究进展,为防治心血管疾病提供重要的参考依据。方法抽取本院2012年体检的1108例中老年人,并将其分为非肥胖(BMI<28kg/m2)无脂肪肝组(795例)、非肥胖伴脂肪肝组(136例)、肥胖(BMI≥28 kg/m2)无脂肪肝组(82例)和肥胖伴脂肪肝组(95例),结合相关临床资料进行回顾性分析。结果经研究,肥胖组脂肪肝发病率为40.7%(72/177),明显高于非肥胖组的14.2%(132/931),两组比较差异具有显著性(P<0.05);男性血清总胆固醇(TC)、甘油三酯(TG)、血糖和女性收缩压(SBP)、TG和血糖等方面比较,肥胖组均高于非肥胖组,比较差异具有显著性(P<0.05);另外,脂肪肝与心血管疾病的危险因素比较,即与高甘油三酯血症、高胆固醇血症、糖尿病或糖耐量异常等比较,差异同样具有显著性(P<0.05)。结论非酒精性脂肪性肝病与心血管疾病存在十分密切的关系,医院在治疗非酒精性脂肪性肝病患者的过程中,需要予以足够的重视,并应有针对性地对心血管疾病进行预防处理,从而达到提高临床治疗效果的目的。

ObjectiveTo study the nonalcoholic fatty liver disease and clinical correlation research progress of cardiovascular disease, provide important reference basis for prevention and treatment of cardiovascular disease hospital.MethodsExtract the hospital physical examination in 2012, 1108 cases of the elderly, and it can be divided into obesity （BMI 〈 28 kg/m2） without fatty liver group 795 examples, the group of 136 cases of obesity with fatty liver, obesity （BMI 28 kg/m2） or no fatty liver group 95 cases 82 cases and obesity with fatty liver group, combined with relevant clinical data were retrospectively analyzed.ResultsThrough research, understand the obese incidence of fatty liver was 40.7% （72/177）, signiifcantly higher than the non-obese group 14.2% （132/931）, similarty between the two groups was statistically signiifcant （P〈0.05）; in male SBP, TG, TC, TG, GLU and women and GLU, obese group were higher than non-obese group, compare the difference was statistically signiifcant （P〈0.05）; in addition compared with a risk factor for cardiovascular disease, fatty liver and high blood triglycerides, hypercholesterolemia, diabetes, or more abnormal glucose tolerance, also has the obvious statistical significance difference （P〈0.05）.ConclusionClinically, nonalcoholic fatty liver disease and cardiovascular disease is very close correlation, the hospital in the treatment of patients with nonalcoholic fatty liver disease in the process of need to give enough attention, and through a targeted to prevent cardiovascular disease treatment, so as to achieve the aim of improve the effect of clinical treatment.